News & Updates
Showing Multidisciplinary articles
Showing

Polycythemia ups risk of MACE, VTE in men on testosterone therapy
Men receiving testosterone therapy (TT) who develop polycythemia are at greater risk for major adverse cardiovascular events (MACE) and venous thromboembolism (VTE) in the first year of therapy, according to a recent study.

Early ivermectin use does not confer benefit for COVID-19
In outpatients with an early diagnosis of COVID-19 at high risk for serious illness, treatment with the antiparasitic ivermectin did not reduce the incidence of hospital admission due to disease progression or of prolonged emergency department observation, findings from the TOGETHER trial suggest.

Elacestrant ups PFS vs SoC ET in ER-positive, HER2-negative advanced breast cancer
Elacestrant, a novel oral selective oestrogen receptor (ER) degrader, significantly improves progression-free survival (PFS) vs standard-of-care (SoC) endocrine therapy (ET) in patients with ER-positive, HER2-negative advanced breast cancer whose disease progressed after 1–2 prior lines of ET and a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, results of the phase III EMERALD trial have shown.





